Merck to evaluate Vaxxas' new skin-patch vaccine delivery platform
This article was originally published in Scrip
Executive Summary
Vaxxas, a young biotech company with a novel vaccine delivery platform, has begun a research collaboration with Merck & Co. The big pharma will evaluate Cambridge, MA-based Vaxxas' Nanopatch technology that induces an immune reaction by targeting vaccines to immune cells immediately below the surface of the skin.